Drug class profile · refreshed daily from federal data

Interleukin-17A Antagonist

2 molecules in this class, $3.63B combined CY2024 Part D spend across 415K claims. Class-level guide below for benefits decision-makers: where the money lives, where the savings live.

Last updated 14 Jul 2026

NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annualOrange Book: weeklyShortages: daily

Class summary at a glance.

Every drug in the Interleukin-17A Antagonist class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 2tracked in Part D
CY24 Part D spend: $3.63Bcombined across class
Total Rx claims: 415K80K unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Secukinumab

Brand: COSENTYX · 290K Part D claims (CY24) · 55K beneficiaries · First FDA approval: 2015-01-21

Brand-only (no generics) 1032 plans require PA

Low NADAC$3961.25

→

Avg plan cost$5561.15

Part D spend $2.59B 1× spread, current vs floor

Class share

71%

of class CY24 spend

View profile →

Ixekizumab

Brand: TALTZ · 125K Part D claims (CY24) · 25K beneficiaries · First FDA approval: 2016-03-22

Brand-only (no generics) 88 plans require PA

Low NADAC$7369.27

→

Avg plan cost$7402.57

Part D spend $1.04B 1× spread, current vs floor

Class share

29%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.